Consensus Monopar Therapeutics Inc.

Stocks

MNPR

US61023L2079

Biotechnology & Medical Research

Market Closed - Nasdaq 07:00:00 31/10/26 am AEDT			5-day change	1st Jan Change
70.32 ^USD	-2.21%		-0.47%	+7.69%

06/10	Monopar Therapeutics Insider Sold Shares Worth $659,387, According to a Recent SEC Filing	MT
21/09	Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to S&P Biotechnology Select Industry Index	CI

Evolution of the Average Target: Monopar Therapeutics Inc.

Evolution of the Target Price: Monopar Therapeutics Inc.

Changes in Analyst Recommendations: Monopar Therapeutics Inc.

d10abce989fc27.LTmXvPV8GY7vDKhJH8UuR37vY5mFiC0G5neho5TDsfs.RwDUjMcEbNq6fvd5KIdeCUmZGe_h_15KqzmU1dGiyIpPXNnXoxZt191f_Q~3dd2eb2302b2135cee91c9e8757dcc39

Analysts' recommendations: Monopar Therapeutics Inc.

14/08	Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald	MT
13/08	Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral From Overweight, Adjusts PT to $119 From $109	MT
09/01	Morgan Stanley Initiates Coverage on Monopar Therapeutics With Overweight Rating, $115 Price Target	MT
15/11	Monopar Therapeutics Shares Fall After Raymond James Downgrade	MT
14/11	Raymond James Downgrades Monopar Therapeutics to Outperform From Strong Buy, Adjusts PT to $123 From $142	MT
11/11	Chardan Research Adjusts Monopar Therapeutics Price Target to $100 From $85, Maintains Buy Rating	MT
11/11	Leerink Partners Initiates Coverage on Monopar Therapeutics With Outperform Rating, $115 Price Target	MT
10/11	Monopar Therapeutics Inc. Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025	CI
14/10/25	Barclays Initiates Monopar Therapeutics Inc at Overweight With $125 Price Target	MT
25/09/25	Chardan Raises Price Target on Monopar Therapeutics to $85 From $60, Keeps Buy Rating	MT
23/09/25	Lake Street Initiates Monopar Therapeutics at Buy With $106 Price Target	MT
09/09/25	BTIG Initiates Monopar Therapeutics at Buy With $87 Price Target	MT
03/09/25	Raymond James Initiates Monopar Therapeutics at Strong Buy With $80 Price Target	MT
07/07/25	Cantor Fitzgerald Initiates Monopar Therapeutics at Overweight With $74 Price Target	MT
23/06/25	Chardan Initiates Monopar Therapeutics at Buy With $60 Price Target	MT
11/01/25	Piper Sandler Initiates Monopar Therapeutics at Overweight With $72 Price Target	MT
11/04/24	JonesTrading Upgrades Monopar Therapeutics to Buy From Hold, Price Target is $2	MT
11/08/23	JonesTrading Downgrades Monopar Therapeutics to Hold From Buy	MT
15/05/23	HC Wainwright Adjusts Monopar Therapeutics' Price Target to $2 From $6, Keeps Buy Rating	MT
30/03/23	Maxim Group Downgrades Monopar Therapeutics to Hold From Buy	MT
28/03/23	Roth MKM Adjusts Price Target on Monopar Therapeutics to $3 From $18, Maintains Buy Rating	MT
28/03/23	EF Hutton Adjusts Price Target on Monopar Therapeutics to $17 From $24, Maintains Buy Rating	MT
10/12/22	Roth Capital Reinstates Monopar Therapeutics at Buy With $18 Price Target	MT
16/08/22	HC Wainwright Adjusts Monopar Therapeutics' Price Target to $6 From $9, Maintains Buy Rating	MT
01/11/21	HC Wainwright Starts Monopar Therapeutics at Buy With $9 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MONOPAR THERAPEUTICS INC.					+84.75%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.41%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+34.46%
	Weighted average by Cap.					+27.08%